167 related articles for article (PubMed ID: 29137110)
1. NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [
Kaloudi A; Lymperis E; Giarika A; Dalm S; Orlandi F; Barbato D; Tedesco M; Maina T; de Jong M; Nock BA
Molecules; 2017 Nov; 22(11):. PubMed ID: 29137110
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
3. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biological properties of [
Rousseau E; Lau J; Zhang Z; Zhang C; Kwon D; Uribe CF; Kuo HT; Zeisler J; Bratanovic I; Lin KS; Bénard F
J Labelled Comp Radiopharm; 2020 Feb; 63(2):56-64. PubMed ID: 31715025
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.
Lau J; Rousseau E; Zhang Z; Uribe CF; Kuo HT; Zeisler J; Zhang C; Kwon D; Lin KS; Bénard F
ACS Omega; 2019 Jan; 4(1):1470-1478. PubMed ID: 30775647
[TBL] [Abstract][Full Text] [Related]
7. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of
Gruber L; Jiménez-Franco LD; Decristoforo C; Uprimny C; Glatting G; Hohenberger P; Schoenberg SO; Reindl W; Orlandi F; Mariani M; Jaschke W; Virgolini I
J Nucl Med; 2020 Dec; 61(12):1749-1755. PubMed ID: 32332143
[TBL] [Abstract][Full Text] [Related]
8. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
9. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
10. Substitution of l-Tryptophan by
Günther T; Deiser S; Felber V; Beck R; Wester HJ
J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
[TBL] [Abstract][Full Text] [Related]
11. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
13. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
14. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
15. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.
Popp I; Del Pozzo L; Waser B; Reubi JC; Meyer PT; Maecke HR; Gourni E
Nucl Med Biol; 2017 Feb; 45():22-29. PubMed ID: 27865999
[TBL] [Abstract][Full Text] [Related]
16.
Wang L; Zhang Z; Merkens H; Zeisler J; Zhang C; Roxin A; Tan R; Bénard F; Lin KS
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744904
[TBL] [Abstract][Full Text] [Related]
17. Imaging Properties and Tumor Targeting of
Gruber L; Decristoforo C; Uprimny C; Hohenberger P; Schoenberg SO; Orlandi F; Mariani MF; Manzl C; Kasseroler MT; Tilg H; Zelger B; Jaschke WR; Virgolini IJ
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428467
[TBL] [Abstract][Full Text] [Related]
18. A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
Ding H; Kothandaraman S; Gong L; Williams MM; Dirksen WP; Rosol TJ; Tweedle MF
Prostate; 2016 Jun; 76(9):783-95. PubMed ID: 26940014
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the new GRPR-antagonist
Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
